Market Research Logo

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

Summary

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin's lymphoma.

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.

Scope

The hematological cancers market is characterized by commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?
  • How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?
Hematological cancers clinical trials have an overall attrition rate of 70.3%.
  • What are the failure rates at individual Phases of clinical development?
  • How do leukemia, lymphoma and myeloma compare in terms of clinical trial failure rate?
The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%.
  • How much of a role will disease prevalence and new product approvals play in market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
Big pharma hold a notable presence in the market.
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • What are the drivers of growth for key companies in the market?
  • How dependent are the key companies on this disease cluster for revenue?
  • Which companies rely heavily on this disease cluster for revenue?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in hematological cancers.
  • Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from hematological cancer products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.


Despite Major Patent Expiries, the Hematological Cancers Market will Exceed $70 Billion by 2022

The market for hematological cancers, which covers leukemia, lymphoma and myeloma, is expected to more than double from $30.7 billion in 2015 to $70.1 billion by 2022, representing a compound annual growth rate of 12.5%, according to business intelligence provider GBI Research.

The company’s latest report* states that this strong growth will occur in spite of a number of key patent expirations for drugs including Rituxan, Gleevec and Velcade, as new drugs hit the market and the prevalence of hematological cancers increases.

Yasser Mushtaq, Senior Analyst for GBI Research, says: “The significant revenue lost by targeted drugs such as Gleevec and Velcade will be counteracted by recently approved drugs and pipeline products. Keytruda (pembrolizumab), for example, which is already marketed for metastatic melanoma, is in Phase III development for multiple myeloma and refractory multiple myeloma. It is also in Phase II development for a number of lymphomas and will therefore contribute to market revenue over coming years.

“A number of drugs currently not marketed will also develop into blockbuster drugs, including selinexor, venetoclax, KTEC-19, and polatuzumab vedotin. Venetoclax in particular is expected to be very lucrative, hitting sales of $3.5 billion in 2022, up from an estimated $155.2 million in 2016. It is a selective, orally administered, first-in-class small molecule therapy in development by AbbVie and Roche, and is indicative of a trend in the market towards expensive targeted therapies, including monoclonal antibodies (mAbs).”

As the use of targeted therapies continues to generate revenue above that of non-specific chemotherapy classes of treatment, key companies investing in the hematological cancers pipeline and targeted therapies will drive the market substantially, according to GBI Research.

Mushtaq continues: “The major market players, including Celgene, Roche, AbbVie, Novartis and Johnson & Johnson, are expected to maintain their strong positions. Of these companies, AbbVie will display the strongest growth, driven by its acquisition of Pharmacyclics, which was already a strong performer in this disease cluster.”

*Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

This report provides analysis of the hematological cancers market space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2015 and forecast to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Epidemiology
2.2.1 Leukemia
2.2.2 Lymphoma
2.2.3 Myeloma
2.3 Pathophysiology
2.3.1 Leukemia
2.3.2 Lymphoma
2.3.3 Myeloma
2.4 Symptoms
2.5 Diagnosis
2.5.1 Leukemia
2.5.2 Lymphoma
2.5.3 Myeloma
2.6 Prognosis and Survival
2.6.1 Survival
2.7 Treatment
2.7.1 Surgery and Radiation Therapy
2.7.2 Stem Cell Transplantation
2.7.3 Pharmacological Therapies
3 Key Marketed Products
3.1 Overview
3.2 Rituxan/Mabthera (rituximab) - Roche
3.3 Gleevec/Glivec (Imatinib) - Novartis
3.4 Revlimid (lenalidomide) - Celgene
3.5 Velcade (bortezomib) - Millennium/Takeda/Johnson & Johnson
3.6 Sprycel (dasatinib) - Bristol-Myers Squibb/Otsuka Pharmaceutical
3.7 Tasigna (nilotinib) - Novartis
3.8 Pomalyst (pomalidomide) - Celgene
3.9 Vidaza (azacitidine) - Celgene
3.10 Kyprolis (carfilzomib) - Onyx/Amgen
3.11 Adcetris (brentuximab vedotin) - Seattle Genetics/Millennium
3.12 Imbruvica (ibrutinib) - AbbVie/Johnson & Johnson
3.13 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Multi-scenario Market Forecast to 2023
4.5.1 Overall Market Size
4.6 Generic Penetration
5 Revenue Forecast by Molecular Target
5.1 Cancer Immunotherapies/Tumor-Associated Antigen
5.2 Signal Transduction
5.3 Receptor Tyrosine Kinases and Ligands
5.4 Revenue and Market Share Analysis by Company
5.4.1 Celgene - Will Revenue Loss Associated with Vidaza, Thalomid and Istodax Impact Celgene’s Position as Market Leader?
5.4.2 Roche - Will the Patent Expiry of Rituxan Significantly Diminish Revenues?
5.4.3 AbbVie/Pharmacyclics - AbbVie Acquiring Pharmacyclics will Drive AbbVie’s Sales Growth
5.4.4 Novartis - Large and Growing Product Portfolio to Maintain Revenue Growth
5.4.5 Johnson & Johnson - Imbruvica and Velcade Partnerships to be Predominant Contributors to Revenue Growth
5.5 Assessment of Key Pipeline Products
5.5.1 Venetoclax (ABT-199) - AbbVie/Roche
5.5.2 KTE-C19 - Kite Pharma
5.5.3 Selinexor (KPT-330) - Karyopharm Therapeutics
5.5.4 Polatuzumab Vedotin (RG-7596) - Roche
5.5.5 Tisagenlecleucel-T (CTL-019) - Novartis
5.5.6 Midostaurin (PKC-412) - Novartis
5.5.7 Conclusion
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 Bibliography
8.2 Table of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Secondary Research
8.5.2 Market Size and Revenue Forecasts
8.5.3 Pipeline Analysis
8.5.4 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016
Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016
Table 3: Hematological Cancers Therapeutics Market, Global, Multiple Myeloma, Prognostic Factors, 2016
Table 4: Hematological Cancers Therapeutics Market, Global, Commonly Used Chemo-Regimens, 2016
Table 5: Hematological Cancers Therapeutics Market, Global, Approved Indications for Rituxan, 2016
Table 6: Hematological Cancers Therapeutics Market, Global, Approved Indications for Gleevec, 2016
Table 7: Hematological Cancers Therapeutics Market, Global, Approved Indications for Revlimid, 2016
Table 8: Hematological Cancers Therapeutics Market, Global, Approved Indications for Velcade, 2016
Table 9: Hematological Cancers Therapeutics Market, Global, Approved Indications for Sprycel, 2016
Table 10: Hematological Cancers Therapeutics Market, Global, Approved Indications for Tasigna, 2016
Table 11: Hematological Cancers Therapeutics Market, Global, Approved Indications for Pomalyst, 2016
Table 12: Hematological Cancers Therapeutics Market, Global, Approved Indications for Vidaza, 2016
Table 13: Hematological Cancers Therapeutics Market, Global, Approved Indications for Kyprolis, 2016
Table 14: Hematological Cancers Therapeutics Market, Global, Approved Indications for Adcetris, 2016
Table 15: Hematological Cancers Therapeutics Market, Global, Approved Indications for Imbruvica, 2016
Table 16: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
Table 17: Hematological Cancers Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
Table 18: Hematological Cancers Therapeutics Market, Global, Forecast Revenue by Company, 2016
Table 19: Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
Table 20: Hematological Cancers Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
Table 21: Hematological Cancers Therapeutics Market, Global, Pipeline Products in Clinical Development, 2016
1.2 List of Figures
Figure 1: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Leukemia, 2015-2022
Figure 2: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Lymphoma, 2015-2022
Figure 3: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Myeloma, 2015-2022
Figure 4: Hematological Cancers Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2016
Figure 5: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022
Figure 6: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Gleevec ($bn), 2006-2021
Figure 7: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022
Figure 8: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Velcade ($bn), 2006-2022
Figure 9: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Sprycel ($bn), 2006-2022
Figure 10: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Tasigna ($bn), 2008-2022
Figure 11: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022
Figure 12: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Vidaza ($bn), 2008-2022
Figure 13: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Kyprolis ($bn), 2012-2022
Figure 14: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Adcetris ($bn), 2011-2022
Figure 15: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Imbruvica ($bn), 2014-2022
Figure 16: Hematological Cancers Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 17: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Stage of Development, Molecule Type and Program Type, 2016
Figure 18: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Stage of Development, 2016
Figure 19: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecule Type, 2016
Figure 20: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Molecular Target, 2016
Figure 21: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecular Target, 2016
Figure 22: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 23: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 24: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 25: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 26: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 27: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 28: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 29: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 30: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 31: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 32: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 33: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 34: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 35: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 36: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 37: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 38: Hematological Cancers Therapeutics Market, Global, Market Size ($bn), 2015-2022
Figure 39: Hematological Cancers Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
Figure 40: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Cancer Immunotherapies/Tumor Associated Antigen ($bn), 2015-2022
Figure 41: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022
Figure 42: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Receptor Tyrosine Kinase and Ligands ($bn), 2015-2022
Figure 43: Hematological Cancers Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 44: Hematological Cancers Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 45: Hematological Cancers Therapeutics Market, Global, Revenue by Product Type, 2015-2022
Figure 46: Hematological Cancers Therapeutics Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
Figure 47: Hematological Cancers Therapeutics Market, Global, Roche Annual Revenue ($bn), 2015-2022
Figure 48: Hematological Cancers Therapeutics Market, Global, AbbVie/Pharmacyclics Annual Revenue ($bn), 2015-2022
Figure 49: Hematological Cancers Therapeutics Market, Global, Novartis Annual Revenue ($bn), 2015-2022
Figure 50: Hematological Cancers Therapeutics Market, Global, Johnson & Johnson Annual Revenue ($bn), 2015-2022
Figure 51: Hematological Cancers Therapeutics Market, Global, Revenue for Venetoclax ($bn), 2015-2022
Figure 52: Hematological Cancers Therapeutics Market, Global, Revenue for KTE-C19 ($bn), 2015-2022
Figure 53: Hematological Cancers Therapeutics Market, Global, Revenue for Selinexor ($bn), 2015-2022
Figure 54: Hematological Cancers Therapeutics Market, Global, Revenue for Polatuzumab Vedotin ($bn), 2015-2022
Figure 55: Hematological Cancers Therapeutics Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2015-2022
Figure 56: Hematological Cancers Therapeutics Market, Global, Revenue for Midostaurin ($m), 2015-2022
Figure 57: Hematological Cancers Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 58: Hematological Cancers Therapeutics Market, Global, Companies by Type, 2016
Figure 59: Hematological Cancers Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Hematological Cancers Specialization, 2016
Figure 60: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, 2015-2022
Figure 61: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, Top Five Companies ($bn), 2015-2022
Figure 62: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
Figure 63: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 64: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 65: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
Figure 66: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
Figure 67: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
Figure 68: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
Figure 69: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report